IL2 and graft versus host disease: Exogenous low-dose IL-2 and IL-2/anti-IL2 complexes decreased Treg efficacy when given at the time of donor T-cell infusion in either xenogeneic or allogeneic GVHD models, respectively, likely though expansion of contaminating cells (200, 201).